Description  Claims  Drawing  Cited references 

WO2007106790A2   [0012]  [0012] 
EP812922A2   [0013]  [0013] 
EP1538218A1   [0014]  [0014] 
US6180349B   [0027] 
US6033854A   [0027] 
US5972602A   [0027] 

Nature   [0008] 
Invest. Ophthalmol. Vis. Sci.   [0009] 
Genes and Immunity   [0010] 
Chinese Medical Journal   [0011] 
Diabetes Care   [0027] 
Molecular Cloning: A Laboratory Manual   [0027] 
Current Protocols in Molecular Biology   [0027] 
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis   [0041] 
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative   [0043] 
Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative   [0043] 
CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study   [0045] 
The 1982 revised criteria for the classification of systemic lupus erythematosus   [0048] 
The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis   [0051] 
The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)   [0053] 
Nomenclature of systemic vasculitides. Proposal of an international consensus conference   [0056] 
Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease   [0059] 
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee   [0061] 
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee   [0066] 
Preliminary criteria for the classification of the acute arthritis of primary gout   [0069] 
Calcium pyrophosphate crystal deposition disease, pseudogout, and articular chondrocalcinosis. In: Arthritis and Allied Conditions   [0076] 
Pseudogout: presentation, natural history, and associated conditions. In: Crystal-induced Arthropathies   [0076] 
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis   [0078] 
An evaluation of criteria for polymyalgia rheumatica   [0081] 
Polymyositis and dermatomyositis (first of two parts)   [0083] 
Polymyositis and dermatomyositis (second of two parts)   [0083] 
Criteria for the diagnosis of familial Mediterranean fever   [0085] 
The autoinflammatory diseases   [0087] 
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors   [0136] 
Emerging roles of TLR7 and TLR9 in murine SLE   [0136] 
TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders   [0136] 
Circulating mitochondrial DAMPs cause inflammatory responses to injury   [0136] 
Neutrophil extracellular traps kill bacteria   [0136] 
Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps   [0136] 
Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense   [0136] 
Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides   [0136] 
Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death   [0136] 
nasal carriage of Staphylococcus aureus and relapse rate in pulmonary Wegener's granulomatosis   [0136] 
Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis   [0136] 
Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis   [0136] 
Novel cell death program leads to neutrophil extracellular traps   [0136] 
Netting neutrophils in autoimmune small-vessel vasculitis   [0136] 
Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies   [0136] 
Neutrophil-derived circulating free DNA (cf-DNA/NETs): a potential prognostic marker for posttraumatic development of inflammatory second hit and sepsis   [0136] 
Diagnostic accuracy of neutrophil-derived circulating free DNA (cf-DNA/NETs) for septic arthritis   [0136] 
Modification and validation of the Birmingham Vasculitis Activity Score (version 3)   [0136] 
A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis   [0136] 
Effects of of didanosine-related depletion of mtDNA in human T lymphocytes   [0136] 
PR3-ANCA in Wegener's granulomatosis prime human mononuclear cells for enhanced activation via TLRs and NOD1/2   [0136] 
Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo   [0136] 
Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses   [0136] 
A novel mechanism of rapid nuclear neutrophil extracellular trap formation in response to Staphylococcus aureus   [0136] 
The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies   [0136] 
Relationship Between Markers of Platelet Activation and Inflammation with Disease Activity in Wegener's Granulomatosis   [0136] 
Association between active Wegener's granulomatosis and anticytoplasmic antibodies   [0136] 
Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis   [0136] 
Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus   [0136] 
Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis   [0136] 
Features of systemic lupus erythematosus in Dnase1-deficient mice   [0136] 
Mutation of DNASE1 in people with systemic lupus erythematosus   [0136] 
Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients   [0136] 
Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9   [0136] 
Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus   [0136] 
N Engl J Med   [0136] 
Poly(I:C) drives type I IFN- and TGFbeta-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis   [0136] 
dsRNA activation of endothelin-1 and markers of vascular activation in endothelial cells and fibroblasts   [0136] 
Vascular damage in giant cell arteritis   [0136]